



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Shan Kang
✉ ksjq62cn@sina.com

†These authors have contributed
equally to this work

RECEIVED 08 May 2023

ACCEPTED 16 May 2023

PUBLISHED 27 June 2023

CITATION

Zuo W-W, Zhao C-F, Li Y, Sun H-Y,
Ma G-M, Liu Y-P and Kang S (2023)
Corrigendum: High expression of PARP1 in
tumor and stroma cells predicts prognosis
and platinum resistance in patients with
advanced epithelial ovarian cancer.
Front. Oncol. 13:1218746.
doi: 10.3389/fonc.2023.1218746

COPYRIGHT

© 2023 Zuo, Zhao, Li, Sun, Ma, Liu and Kang.
This is an open-access article distributed
under the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

Wei-Wei Zuo^{1,2†}, Chun-Fang Zhao^{3†}, Yan Li⁴, Hai-Yan Sun¹,
Guo-Ming Ma⁵, Yue-Ping Liu⁶ and Shan Kang^{1*}

¹Department of Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China, ²Department of Gynecology, Tangshan People's Hospital, Tangshan, China, ³Department of Histoplasty and Embryology, Hebei Medical University, Shijiazhuang, China, ⁴Department of Molecular Biology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China, ⁵Department of gastrointestinal surgery, Tangshan People's Hospital, Tangshan, China, ⁶Department of Pathology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China

KEYWORDS

advanced epithelial ovarian cancer, PARP1, cytokeratin, platinum resistance, prognosis

A Corrigendum on

[High expression of PARP1 in tumor and stroma cells predicts different prognosis and platinum resistance in patients with advanced epithelial ovarian cancer](#)

by Zuo W-W, Zhao C-F, Li Y, Sun H-Y, Ma G-M, Liu Y-P and Kang S (2022) *Front. Oncol.* 12:931445. doi: 10.3389/fonc.2022.931445

In the published article, there was an error in the Funding statement. The Grant number for the Natural Science Foundation of Hebei Province was displayed as “H20202063”. The correct Funding statement appears below.

The correct Funding statement is “This work was supported by grants from the Natural Science Foundation of Hebei Province (Grant number: H2020206385).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.